The approved merger will be submitted to the Ontario Superior Court of Justice for final court approval on or about February 27, 2007. If court approval is obtained and other customary conditions to closing are satisfied the transaction is expected to close on or about February 28, 2007, at which time all Tm Bioscience shareholders will be entitled to receive 0.06 Luminex common shares in exchange for each Tm Bioscience common share. Read More….

Chemists are currently able to synthetically produce almost any compound, but they must typically resort to expensive, complex processes that can require dozens of individual steps. Such natural product syntheses have traditionally relied on the ubiquitous use of “protecting groups,” which are extra compounds chemists use to shield reactive portions of a molecule during specific stages of a synthesis scheme. Read More….

The publication of the molecular structure of the insulin receptor last September, led by Australia’s Colin Ward, was a milestone in the life sciences. Fiona Wylie profiles the man behind the receptor.The publication of the molecular structure of the insulin receptor last September, led by Australia’s Colin Ward, was a milestone in the life sciences. Fiona Wylie profiles the man behind the receptor.

Four years ago Matthew Freeman discovered the first of a new family of membrane-active protease enzymes, rhomboids. They disturbed the sleep of biophysicists, but are now inspiring drug researchers to dream.